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In this issue of the Journal, Dangas et al. (1) assessed the
incidence of vascular complications at the Washington
Hospital Center following percutaneous coronary interven-
tions (PCI) when arteriotomy closure devices (ACD) were
used to achieve hemostasis of the femoral artery versus when
manual compression was used. Their main finding was that
three vascular complications—hematoma, hematocrit drop
of .15%, and the need for surgical repair of the access
site—were approximately twice as frequent in patients in the
ACD group than in the manual compression group.
First and foremost, Dangas et al. (1) are to be com-
mended for their effort, which represents important and
useful information not only to clinicians but also to other
stakeholders, including patients, regulated industry and the
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Food and Drug Administration (FDA). All of us share in a
mutual responsibility to continue to assure the safety and
effectiveness of marketed medical devices. Studies like this
help achieve that goal.
To put their study by Dangas et al. (1) in perspective, we
reviewed several previous studies that compared the inci-
dence of serious complications associated with ACDs with
those from manual compression (2–13). Most of these
studies found no significantly greater incidence with the use
of ACDs (2–10). Besides the lack of power to detect
small-to-moderate differences in most of these studies, use
factors must be taken into account. These factors include
improper patient selection, insufficient or inadequate train-
ing of the device operator, and poor recognition of postpro-
cedure patient problems. Improper patient selection might
include patients that are obese, very slight of build, or have
a history of high blood pressure and peripheral vascular
disease. Improper training might occur when a user has less
than optimal training or experience or attempts to use the
device with no training. Adverse events due to these
problems may involve postprocedure patient problems that
are not recognized until the patient’s status is severely
compromised. Some institutions, however, might be more
proficient in the use of these devices (especially those that
participate in clinical trials) and, therefore, experience lower
complication rates than other institutions.
Conversely, some studies have found significantly greater
complication rates with ACDs (specifically, collagen plug-
type devices) than with manual compression (11–13). In
addition, the study by Shrake (13), like the Dangas et al. (1)
study, found statistically significant higher rates of vascular
complication with one brand (Angio-Seal) compared to
others. The study by Dangas et al. (1), however, shows a
tendency to higher rates, with all but one of the other
devices as well (although not so statistically significantly).
One of the potential problems with this study, as with any
epidemiologic study, concerns the manner in which subject
(i.e., those who had ACDs used on them) and control status
(i.e., those who had manual compression applied to them)
was determined. In this study, as the investigators state,
determining subject and control status was by the preference
of the individual physicians. This raises the possibility that
subjects and controls may have differed in substantial ways,
and that these differences might have contributed to some or
all of the differences in clinical outcomes.
The investigators (1) attempted to deal with this potential
problem by identifying several potential confounding vari-
ables and then statistically controlling for them in the
multivariate analysis. It is unclear to us why some of the
baseline characteristics and procedural variables identified
by the researchers in Tables 1 and 2 of their study were
apparently not included in the multivariate analysis. In
particular, previous myocardial infarction, history of PCI
and use of debulking devices were all significantly more
frequent in the control group than in the subject group, and
yet they were apparently not considered in the multivariate
analysis. Nevertheless, given the small differences in these
variables between the two groups it does not seem at all
likely that failure to control for them would have substan-
tially influenced the final results.
In addition, it would have been useful to know something
about how physicians made the determination of whether or
not to use an ACD—in particular, did they preferentially,
but unknowingly, choose patients who were at high risk for
complications for ACD use? If so, that could have ac-
counted for some or all of the differences in clinical
outcomes between the two groups. However, we can think
of no reason to believe that that was the case.
A final point on the issue of confounding concerns
activated clotting times (ACTs). Although Table 2 in the
Dangas et al. (1) report notes the average final ACT values
(presumably at the end of the PCI procedure) for both the
subjects and controls, the more clinically, likely and signif-
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icant difference in ACTs would be the difference noted at
the time either the ACD or manual compression was
applied. Because ACDs are applied right after the proce-
dure, ACTs for the subjects would approximate the final
procedural value (i.e., on average 277 s), whereas ACTs for
the controls would be ,150 s (per hospital protocol). The
investigators rightly stress in their Discussion section that
this could have been a reason for the higher complication
rate in the ACD group. If ACT values at the time of
manual compression are available for the control group,
then entering the subject and control values into their
regression equations could reveal to what extent this variable
was responsible for the observed differences in complication
rates.
One aspect of the multivariate analysis was somewhat
confusing. The ACDs were found to be associated with
major hematoma (as they were in the univariate analysis)
with an odds ratio (OR) of 4.28 and a p value of ,0.001, yet
ACDs were not noted to be significantly associated with
“any vascular complication.” This is very hard to understand,
for hematoma accounted for almost half of the vascular
complications noted in this study, and ACDs were also
significantly associated in the univariate analysis with he-
matocrit drop, “major hematoma” and surgical repair. Thus,
ACDs were significantly associated with vascular complica-
tions in the Dangas et al. (1) study, with a relative risk (RR)
of approximately 2, which together accounted for 99 of 111
(89%) vascular complications identified in this study, and
yet ACDs were not associated with “any vascular compli-
cation” in the multivariate analysis when controlled for age,
body surface area and gender. We believe that identification
of the reason for this perplexing finding could be very
interesting.
A couple of points should be made with regard to
ascertainment of complications. Given the retrospective
nature of the study, it is unclear to what extent there was any
differential recording of complications (e.g., hematoma) in
the medical or other record by subject or control status. One
could argue that this could more likely occur with “softer”
findings (such as hematoma) than with “harder” outcomes
(such as surgical repair). But the differential recording would
have to be systematic to bias the results, and no evidence or
likely scenario suggests that. In addition, it should be noted
that this study is limited to in-hospital complications and
does not capture postdischarge events. Both overall and
complication-specific risk estimates would be affected to the
extent that postdischarge complications are more likely to
occur in subjects or controls.
The investigators rightly note in the first paragraph of
their Discussion section that ACDs may result in rapid
hemostasis, early ambulation, and “ideally achieve potentially
fewer complications.” Yet their study suggests just the
opposite—that ACDs result in more, not fewer, complica-
tions. This issue is obviously of importance to the FDA.
The question: “Do ACDs cause an excess of serious com-
plications and deaths as compared with manual compres-
sion?” is critical to the FDA and must be assessed given the
totality of evidence and the benefits of the device.
In their Limitations section the investigators note, among
other things, two issues that would appear to make the
results of their study of limited usefulness. One is their
statement that: there was no uniform, laboratory-initiated,
standardized training for ACD selection and application.
We believe that this fact, from a practical standpoint, may
actually make these study results more, rather than less,
important. Clinical trials that avoid the above-noted prob-
lem may sometimes demonstrate greater device safety and
effectiveness than will later be seen for a given device “in the
real world” after it is marketed. This would tend to occur if
the clinical investigators are better trained in the use of
complicated and difficult-to-use medical devices than most
practitioners, who will actually use the device after it is
marketed. A related problem, which applies both to clinical
trials and to this type of study, is that the results of these
studies apply to specific clinical setting(s) and may not be
generalizable to the larger universe of clinical settings. One
way to address this problem is to design a population-based
study to examine these issues. To date, none have been
conducted.
The investigators note at the end of their report that their
results may not be applicable to newer “generations” of
ACDs. This type of statement is probably applicable in
greater or lesser degree to most studies of medical devices, as
changes that presumably result in improvements are con-
tinually made during the life cycles of most of them.
Nevertheless, we believe that the evidence of serious and
potentially fatal complications noted in the Dangas et al. (1)
study warrants continued research and monitoring. It is
important to learn about these problems because they may
be applicable to subsequent generations.
Finally, the Dangas et al. (1) study must be viewed in the
broader context of postmarket surveillance. Once a product
is marketed, the FDA routinely receives reports of device-
related adverse events and product problems through its
nationwide voluntary and mandatory Medical Device Re-
porting (MDR) system (14). Indeed, by the end of year
2000, a total of 1,879 reports of serious injuries (mostly
hemorrhage, hematoma and infection) and 36 reports of
deaths associated with the use of ACDs had been received
(15). The reports are reviewed individually from a variety of
perspectives (i.e., the device, the user and the patient) that
might signal problems—for instance, with manufacturing,
labeling (including instructions and training), device design
(e.g., one that induces human error) or biocompatibility.
Although reports of the type received (e.g., hematoma) are
expected given the nature of the device, the relative novelty
of the technology, and the fact that a variety of less
experienced clinicians will use the device in a wider array of
patients, the severity of some of the events and the shear
number do arouse concern.
Although the MDR system serves a vital “signaling”
function of potential product problems, its limitations
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preclude us from making risk assessments that studies of the
kind discussed here can. The important limitations in this
regard are: 1) significant underreporting of actual incidents;
2) lack of use data to derive actual incident rates; and most
germane to the Dangas et al. (1) study, 3) similar compli-
cations following PCI—where manual compression rather
that an ACD is used for hemostasis—are not reportable.
Therefore, we are not able to conclude from the MDR
reports alone that hemorrhagic complications following
PCI are any more frequent when ACDs are used than when
they are not used. We rely on observational studies in the
postmarket period to assess further the risk/benefit ratio as
product development and improvement occurs.
To be most effective, however, these studies need to: 1)
address specific public health questions, 2) be timely, and 3) be
considered important by not only the clinical community but
also by the regulated industry and the FDA. Depending upon
the specific public health question, various study approaches
and designs may be pursued to address the issue most effi-
ciently and effectively. Although the FDA has the statutory
authority to mandate manufacturers to conduct postmarket
studies (either as a condition of approval for marketing or “for
cause” later in the postmarket period), the agency prefers to
work collaboratively with clinicians and the regulated industry
to enhance and continue to develop a postmarket framework
that provides early signals of potential problems and that
addresses new and ongoing concerns with effective postmarket
tools. To that end, the FDA has been recently working with
the clinical community and regulated industry to foster the
development and use of cardiovascular registries. It is tools such
as these, and the continuing applied research by the clinical
community as evidenced by the report by Dangas et al. (1), that
will provide the postmarket surveillance needed to protect the
public health.
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